Cefaclor is a second generation cephalosporin antibiotics chemically related to penicillin widely used in treatment of respiratory, urinary and skin infections most affective against gram negative organism. The objective of this work is to retardant polymers were employed with varying concentrations and also in combination in different ratio to get promising concentration for extended release matrix tablets. Matrix tablets of cefaclor were formulated using hydrophilic swellable polymers HPMC E-15 and HPMC K-100M with lactose as diluents. LHPC, Colliodal silicon dioxide, Talc, Mg. stearate and Crosscarmelose sodium were used as excipients. All the formulations prepared were found to comply with the weight variation, friability, drug content uniformity and in-vitro dissolution studies.
Cite this article:
Afreen Bano, Bharti Bairagi, Deepika Sahu. Design, Formulation and Evaluation of Cefaclor extended release Matrix Tablet. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):155-158. doi: 10.5958/0975-4377.2020.00026.9
Afreen Bano, Bharti Bairagi, Deepika Sahu. Design, Formulation and Evaluation of Cefaclor extended release Matrix Tablet. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):155-158. doi: 10.5958/0975-4377.2020.00026.9 Available on: https://rjpdft.com/AbstractView.aspx?PID=2020-12-3-3
1. The Merck Index, 13th edition, Merck and company, INC, White House Station, NJ, 324 (2001).
2. Hebert A, Sigman E, Levy M Serum sickness reactions from cefaclor in children. Dermatol, 1991; 25:805-8.
3. Parra F, Igea J, Martín J, Alonso M Sainz T, Serum sickness-like syndrome associated with cefaclor therapy, Allergy, J. Am. Acad,1992; 47: 439–440.
4. King BA, Geelhoed GC Adverse skin and joint reactions associated with oral antibiotics in children the role of cefaclor in serum sickness like reactions, J Paediatr Child Health, 2003; 39 (9): 677–681.
5. Banker GS, Rhodes CT Modern Pharmaceutics, 4th ed. Marcel Dekker Inc, New York: 1992: p.501-502.
6. Rowe RC, Sheskey PJ, Weller PJ. Handbook of Pharmaceutical Excipients, 4th ed. Pharmaceutical press and the American Pharmaceutical Association. 2006: p. 108-111, 161-164, 297- 300, 354-357.
7. Wadke DA, Serajuddin TM and Jacobson H. Preformulation Testing. In: Lieberman HA, Lachman L, Pharmaceutical Dosage Form; Tablets; Vol-1, Marcel Dekker, New York: 1990: p. 1, 13,54.
8. Niazi SK, Hand book of Preformulation. Characterization of Biopharmaceutical Drugs, Informa Healthcare, New York, London 2007: p. 329-390.
9. Mutalik S, Naha A, Usha AN, Ranjith AK, Musmade PK Manoj, Anju P and Prasanna S Preparation, in vitro, preclinical and clinical evaluations of once daily sustained release tablets of aceclofenac. Arch Pharm Res, 2007; 30 (2): 222-234.
10. Wadke DA, Serajuddin TM and Jacobson H. Preformulation Testing. In: Lieberman HA, Lachman L, Pharmaceutical Dosage Form; Tablets; Vol-1, Marcel Dekker, New York: 1990: p. 1, 13, 54.
11. Pillay V, Fassihi R Evaluation and comparison of dissolution data derived from different modified release dosage forms: an alternative method. Journal of Controlled Release, 1998; 55: 45-55.
12. International Conference on Harmonization (ICH), Harmonized Tripartite guideline for stability testing of new drugs substances and Products Q1A(R2) 2003 Feb 6.
13. Grimm W Extension of The international conference on harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev Ind Pharm, 1998; 24: 313-325.